This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LEWIS L. HAAS, M.D.

AMA Arch Intern Med. 1957;100(2):190-195.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The 23 mev betatron has been in medical use at the University of Illinois since 1949. It is our experience that the majority of the medical profession has still only very vague ideas about the clinical possibilities and limitations of this megavoltage therapy. I try to outline here our present views about the possible indications and expectations after seven years' experience.

When we started we did not expect a dramatic change in cancer cure by the use of the new type of radiation. From a pathological point of view, the irradiation is a local treatment, while the cancer is very frequently a systemic disease at the time of the irradiation. Either it is multifocal in origin, or cancer cells have already spread into the lymphatic or vascular pathways of generalization. A local treatment cannot cure a cancer which is not localized. From a biophysical point of view, the biological effect . . . [Full Text PDF of this Article]

Author Affiliations
Chicago

From the Department of Radiology, University of Illinois College of Medicine.

Footnotes
Accepted for publication April 3, 1957.

Read before the Annual Meeting of the Wisconsin Radiological Society, Oct. 12-14, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?